Companies · Other Health Care

Cardionomic, Inc.

New Brighton · Other Health Care

Diligence memoA one-page analyst read on Cardionomic, Inc. — recommendation, valuation, rhythm, risks.
$51.7M
Total raised · real
4
Rounds
0.3×
Latest step-up
Top 9%
Sector rank · raised
Series B
Latest stage · inferred · Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Cardionomic, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.20× the median modeled value of Series B Other Health Care companies in 2019–2021 (78 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Cardionomic, Inc. is one of 5377 Other Health Care companies tracked from New Brighton. By capital raised it ranks among the largest (ahead of 92% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2021-09-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries B · 2015-10-02 Raised $22M (real) Modeled valuation $484M (est)$22M$484MSeries B2015Series B · 2018-04-17 Raised $9.0M (real) Modeled valuation $199M (est)$9.0M$199MSeries B2018Series B · 2020-02-07 Raised $16M (real) Modeled valuation $351M (est)$16M$351MSeries B2020Series B · 2021-09-21 Raised $5.0M (real) Modeled valuation $76M (est)$5.0M$76MSeries B2021+$9.0M+$16M+$5.0MCumulative $52M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$21.8M · 2015
Series B extension$9.0M · 2018
Series B extension$15.8M · 2020
Series B extension$5.0M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$76.3M
Base estimate est.
$11.8M
Conservative case
$232.3M
Upside case
$27.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series B · modeled $483.7M · 2015-10-022015Series B · modeled $199.4M · 2018-04-17Series B · modeled $351.1M · 2020-02-07Series B · modeled $76.3M · 2021-09-212021
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
4.8 yr
Elapsed time used
4.8 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
24 mo
Avg between rounds
$8.7M/yr
Capital velocity
10.7 yr
On record since
2015
First round
4
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 21× above median
This company$51.7M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.3× of median
This company$5.0M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 3.5× above median
This company$76.3M
Sector median$22.1M

Raised more than 92% of sector peers (real $). Modeled value above 74% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #67 of 78.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)KSMS Holdings, LLC · Series B Raised $40.0M · modeled $885.1M (est)Infab HoldCo, Inc. · Series B Raised $36.5M · modeled $807.5M (est)Aquity Holdings, Inc. · Series B Raised $36.0M · modeled $797.6M (est)MHH Management Holdco, LLC · Series B Raised $35.1M · modeled $777.6M (est)Earli Inc. · Series B Raised $40.0M · modeled $757.1M (est)Encore Dermatology, Inc. · Series B Raised $89.6M · modeled $729.9M (est)National Spine & Pain Centers Holdings, LLC · Series B Raised $32.0M · modeled $708.9M (est)In Vitro Sciences, LLC · Series B Raised $31.5M · modeled $697.9M (est)Lotus Parent, Inc. · Series B Raised $31.2M · modeled $690.4M (est)Iron Oak Holdings LLC · Series B Raised $30.0M · modeled $664.6M (est)Squid Ink, Inc. · Series B Raised $30.2M · modeled $621.4M (est)Predict Innovation Investors, Llc · Series B Raised $27.9M · modeled $617.4M (est)Cardionomic, Inc. (this company) Raised $51.7M · modeled $76.3M (est)Cardionomic, Inc.
CompanyStageRaised · realValue · estvs peer med.
KSMS Holdings, LLCSeries B$40.0M$885.1M2.36×
Infab HoldCo, Inc.Series B$36.5M$807.5M2.16×
Aquity Holdings, Inc.Series B$36.0M$797.6M2.13×
MHH Management Holdco, LLCSeries B$35.1M$777.6M2.08×
Earli Inc.Series B$40.0M$757.1M2.02×
Encore Dermatology, Inc.Series B$89.6M$729.9M1.95×
National Spine & Pain Centers Holdings, LLCSeries B$32.0M$708.9M1.89×
In Vitro Sciences, LLCSeries B$31.5M$697.9M1.86×
Lotus Parent, Inc.Series B$31.2M$690.4M1.84×
Iron Oak Holdings LLCSeries B$30.0M$664.6M1.78×
Squid Ink, Inc.Series B$30.2M$621.4M1.66×
Predict Innovation Investors, LlcSeries B$27.9M$617.4M1.65×
Cardionomic, Inc. this companySeries B$51.7M$76.3M0.20×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$21.8M2015-10-02$121.3M$483.7M85%
Series B$9.0M2018-04-17$50.0M$199.4M90%
Series B$15.8M2020-02-07$88.0M$351.1M90%
Series B$5.0M2021-09-21$27.8M$76.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$21.8M2015-10-02
    • First recorded raise — entered as Series B.
    • 12 investors on this round.
  2. Series B$9.0M2018-04-17
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  3. Series B$15.8M2020-02-07
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 1.8× larger than the prior — scaling up.
    • 4 investors on this round.
  4. Series B$5.0M2021-09-21
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 3.2× smaller than the prior — bridge or down round.
    • 4 investors on this round.
Intelligence
2023 ~Q3
Modeled next raise · ~24mo cadence
$5.0M
Modeled next size est.range $5.0M$8.0M
0.3×
Last step-up
$8.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ali Behbahani16 other2015-10
Tara Butler11 other2018-04
Brian Farley4 other2021-09
Michael DeMane3 other2015-10
Akhil Saklecha2 other2021-09
Karen Shanahan2 other2015-10
Jay Graf1 other2015-10
William Abraham1 other2015-10
Dan Kaiser2015-10
John Heavey2018-04
Steve Goedeke2015-10
Tony Borowicz2018-04
Registry & provenance

Cardionomic, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1655807
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Rotation Medical IncOther Health CareSeries B$51.1M$177.2Mnetwork2 shared operators · same sector · same stage
Renovia Inc.Other Health CareSeries B$57.5M$348.6Mnetwork1 shared operator · same sector · same stage
Oculeve, Inc.Other Health CareSeries B$33.2M$368.9Mnetwork1 shared operator · same sector · same stage
Centerline Biomedical, Inc.BiotechnologySeries B$71.8M$55.1Mnetwork2 shared operators · same stage
Neuronetics, Inc.Other Health CareSeries B$118.7M$332.3Mnetwork1 shared operator · same sector · same stage
Colorescience IncOther Health CareSeries B$51.2M$66.5Msame sector · same stage
NovaSom, IncOther Health CareSeries B$53.9M$82.0Msame sector · same stage
AVAVA, Inc.Other Health CareSeries B$48.8M$78.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
CardioNXT, Inc.Other Health CareSeed$74.4M92%
Cardialen, Inc.Other Health CareSeries B$71.9M89%
CardioWise, Inc.Other Health CareSeed$8.0M89%
Heart Test Laboratories, Inc.Other Health CareSeries A$5.6M88%
Cardia, Inc.Other Health CareSeed$9.0M87%
National Cardiac Inc.Other Health CarePre-Seed$17.9M87%
Myocardial Solutions, Inc.Other Health CareSeries A$18.7M87%
Biocardia Lifesciences, Inc.Other Health CareSeries A$88.3M87%
Frequently asked
How much funding has Cardionomic, Inc. raised?
Cardionomic, Inc. has raised approximately $51.7M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Cardionomic, Inc.'s estimated valuation?
Provath's modeled valuation for Cardionomic, Inc. is approximately $76.3M (modeled range $11.8M–$232.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cardionomic, Inc. at?
Cardionomic, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Sep 21.
What does Cardionomic, Inc. do and where is it based?
Cardionomic, Inc. operates in the Other Health Care sector, based in New Brighton.
Explore related

See where Cardionomic, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cardionomic, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.